GlassScriptPhysician profile
James N Kim
NPI 1942381090
$8,405.72
in general payments reported to CMS, 2019-2025
41 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $144 · 2021: $204 · 2022: $1,308 · 2023: $3,017 · 2024: $1,411 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,078 · Travel and Lodging: $1,926 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,078.18 |
| Travel and Lodging | $1,926.46 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,010.26 | 2022-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $795.96 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $456.83 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $451.39 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $393.67 | 2022-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $379.49 | 2024-2025 | |
| Harmony Biosciences LLC | $263.99 | 2023-2025 | Wakix |
| Axsome Therapeutics, INC. | $248.30 | 2023-2025 | Sunosi |
| Genzyme Corporation | $213.32 | 2022-2025 | |
| Boston Scientific Corporation | $194.63 | 2021-2022 | |
| Verona Pharma, INC. | $181.95 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.40 | 2019-2023 | Ofev |
| Merck Sharp & Dohme LLC | $159.19 | 2019-2025 | Zerbaxa, Recarbrio, Keytruda |
| Pulmonx Corporation | $150.91 | 2023-2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Avadel Cns Pharmaceuticals, LLC | $146.66 | 2024-2025 | Lumryz |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.